US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection

Health Secretary Robert F. Kennedy Jr. said at a Senate hearing that he played no role in the FDA's decision not to approve Replimune's drug for advanced skin cancer, placing the decision with FDA Commissioner Dr. Marty Makary. The article is a factual clarification around regulatory responsibility rather than a direct update on the drug's prospects. Market impact should be limited unless it signals broader changes in FDA review dynamics.

Analysis

Health Secretary Robert F. Kennedy Jr. said at a Senate hearing that he played no role in the FDA's decision not to approve Replimune's drug for advanced skin cancer, placing the decision with FDA Commissioner Dr. Marty Makary. The article is a factual clarification around regulatory responsibility rather than a direct update on the drug's prospects. Market impact should be limited unless it signals broader changes in FDA review dynamics.